UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 913

Sortiert nach

Review article: loss of response to anti‐TNF treatments in Crohn’s disease

Alimentary pharmacology & therapeutics, 2011-05, Vol.33 (9), p.987-995

2011

Volltextzugriff (PDF)

Early drug and anti‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (2), p.212-218

2018

Volltextzugriff (PDF)

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

Alimentary pharmacology & therapeutics, 2014-09, Vol.40 (6), p.620-628

2014

Volltextzugriff (PDF)

Editorial: restoring therapeutic infliximab drug levels in patients with loss of response—pharmacokinetics and anti‐drug antibodies as useful guidance tools

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (6), p.845-846

Ben‐Horin, S.

2018

Volltextzugriff (PDF)

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

Journal of Crohn's & colitis, 2014-06, Vol.8 (6), p.443-468

2014

Volltextzugriff (PDF)

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (2), p.276-282

2017

Volltextzugriff (PDF)

Undetectable anti‐TNF drug levels in patients with long‐term remission predict successful drug withdrawal

Alimentary pharmacology & therapeutics, 2015-08, Vol.42 (3), p.356-364

2015

Volltextzugriff (PDF)

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis

Alimentary pharmacology & therapeutics, 2016-06, Vol.43 (12), p.1293-1299

2016

Volltextzugriff (PDF)

Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor

Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (8), p.1117-1125

2018

Volltextzugriff (PDF)

Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

Alimentary pharmacology & therapeutics, 2018-09, Vol.48 (5), p.575-576

2018

Volltextzugriff (PDF)

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors’ reply

Alimentary pharmacology & therapeutics, 2017-03, Vol.45 (5), p.760-762

2017

Volltextzugriff (PDF)

Antigenic response to CT‐P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition

Alimentary pharmacology & therapeutics, 2018-09, Vol.48 (5), p.507-522

2018

Volltextzugriff (PDF)

The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

Alimentary pharmacology & therapeutics, 2011-02, Vol.33 (3), p.349-357

2011

Volltextzugriff (PDF)

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

Journal of Crohn's and colitis, 2009-06, Vol.3 (2), p.47-91

2009

Volltextzugriff (PDF)

Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines

Alimentary pharmacology & therapeutics, 2012-07, Vol.36 (2), p.145-150

2012

Volltextzugriff (PDF)

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD

Alimentary pharmacology & therapeutics, 2012-03, Vol.35 (6), p.714-722

2012

Volltextzugriff (PDF)

Re-phrasing the question: A simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease

United European gastroenterology journal, 2017-10, Vol.5 (6), p.880-886

2017

Volltextzugriff (PDF)

The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Gut, 2011-01, Vol.60 (1), p.41-48

2011

Volltextzugriff (PDF)

Inflammatory Bowel Disease [IBD] and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD

Journal of Crohn's and colitis, 2019-05, Vol.13 (6), p.686-692

2019

Volltextzugriff (PDF)

Diffusion-weighted imaging in quiescent Crohn's disease: correlation with inflammatory biomarkers and video capsule endoscopy

Clinical radiology, 2017-09, Vol.72 (9), p.798.e7-798.e13

2017

Volltextzugriff (PDF)

Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD - authors' reply

Alimentary pharmacology & therapeutics, 2012-09, Vol.36 (5), p.501-501

2012

Volltextzugriff (PDF)

Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease

Digestive diseases and sciences, 2017-03, Vol.62 (3), p.755-760

2017

Volltextzugriff (PDF)

The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease

Cellular immunology, 2009, Vol.258 (2), p.115-122

2009

Volltextzugriff (PDF)

The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease

Cellular immunology, 2009, Vol.258 (2), p.115-122

2009

Volltextzugriff (PDF)

Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines

Gut, 2009-03, Vol.58 (3), p.396-403

2009

Volltextzugriff (PDF)

1 – 25 von 913

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(828)
Mit Volltextzugriff
(837)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(382)
Life Sciences & Biomedicine
(337)
Gastroenterology & Hepatology
(230)
Humans
(226)
Female
(129)
Male
(125)
Adult
(116)
Middle Aged
(85)
Inflammatory Bowel Disease
(83)
Crohn's Disease
(82)
Gastroenterology And Hepatology
(59)
Ulcerative Colitis
(58)
Young Adult
(58)
Retrospective Studies
(57)
Gastroenterology
(54)
Infliximab
(49)
Crohn Disease - Drug Therapy
(47)
Inflammatory Bowel Diseases - Drug Therapy
(45)
Treatment Outcome
(44)
Aged
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Review article: loss of response to anti‐TNF treatments in Crohn’s disease

Early drug and anti‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

Editorial: restoring therapeutic infliximab drug levels in patients with loss of response—pharmacokinetics and anti‐drug antibodies as useful guidance tools

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

Undetectable anti‐TNF drug levels in patients with long‐term remission predict successful drug withdrawal

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis

Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor

Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors’ reply

Antigenic response to CT‐P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition

The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD

Re-phrasing the question: A simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease

The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Inflammatory Bowel Disease [IBD] and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD

Diffusion-weighted imaging in quiescent Crohn's disease: correlation with inflammatory biomarkers and video capsule endoscopy

Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD - authors' reply

Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease

The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease

The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease

Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines

Suchergebnisse filtern